Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by ...
Helsinki3y
MMN2018: The 8th Mismatch Negativity conference
MMN2018: 8th Mismatch Negativity conference “MMN from basic science to clinical applications” The 8th Mismatch Negativity conference “MMN from basic science to clinical applications”, celebrating 40th ...
Helsinki3y
What is the MMN2018 conference?
The 8th Mismatch Negativity conference “MMN from basic science to clinical applications”, celebrating 40th anniversary of the discovery of the MMN and 20th anniversary of the MMN conferences, will be ...